Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia

Letícia Antunes Muniz Ferreira, Juliana Capannacci, Newton Key Hokama, Célia Regina Nogueira, Michele Ceccarelli, Luigi Cerulo, Fulvio D’Angelo, Paula de Oliveira Montandon Hokama

Research output: Contribution to journalArticle

Abstract

Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib). A pool of total leukocytes from healthy donors was considered as control group. Expression analyses were performed for 768 miRNAs by RT-qPCR array. Bioinformatic tools were used to identify significant pathways and interaction networks. We found 80 deregulated miRNAs between the groups and, according to bioinformatic analysis, they are involved in different pathways, including molecular mechanisms of cancer. The study allows better understanding of disease molecular behavior, and it is useful for possible monitoring CML treatment and prognostic biomarkers identification.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 1 Jan 2018
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MicroRNAs
Computational Biology
Leukemia, Myeloid, Chronic Phase
Biological Phenomena
Philadelphia Chromosome
Leukocytes
Stem Cells
Biomarkers
Imatinib Mesylate
Tissue Donors
Pathology
Control Groups
Neoplasms
Therapeutics

Keywords

  • Biomarkers
  • chronic phase
  • gene expression regulation
  • imatinib mesylate
  • leukemia
  • microRNAs
  • myeloid
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ferreira, L. A. M., Capannacci, J., Hokama, N. K., Nogueira, C. R., Ceccarelli, M., Cerulo, L., ... de Oliveira Montandon Hokama, P. (Accepted/In press). Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia. Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2018.1499905

Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia. / Ferreira, Letícia Antunes Muniz; Capannacci, Juliana; Hokama, Newton Key; Nogueira, Célia Regina; Ceccarelli, Michele; Cerulo, Luigi; D’Angelo, Fulvio; de Oliveira Montandon Hokama, Paula.

In: Leukemia and Lymphoma, 01.01.2018.

Research output: Contribution to journalArticle

Ferreira, Letícia Antunes Muniz ; Capannacci, Juliana ; Hokama, Newton Key ; Nogueira, Célia Regina ; Ceccarelli, Michele ; Cerulo, Luigi ; D’Angelo, Fulvio ; de Oliveira Montandon Hokama, Paula. / Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia. In: Leukemia and Lymphoma. 2018.
@article{20b5a7fc193c4575932aed28500383ad,
title = "Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib). A pool of total leukocytes from healthy donors was considered as control group. Expression analyses were performed for 768 miRNAs by RT-qPCR array. Bioinformatic tools were used to identify significant pathways and interaction networks. We found 80 deregulated miRNAs between the groups and, according to bioinformatic analysis, they are involved in different pathways, including molecular mechanisms of cancer. The study allows better understanding of disease molecular behavior, and it is useful for possible monitoring CML treatment and prognostic biomarkers identification.",
keywords = "Biomarkers, chronic phase, gene expression regulation, imatinib mesylate, leukemia, microRNAs, myeloid, Philadelphia chromosome",
author = "Ferreira, {Let{\'i}cia Antunes Muniz} and Juliana Capannacci and Hokama, {Newton Key} and Nogueira, {C{\'e}lia Regina} and Michele Ceccarelli and Luigi Cerulo and Fulvio D’Angelo and {de Oliveira Montandon Hokama}, Paula",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1499905",
language = "English",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia

AU - Ferreira, Letícia Antunes Muniz

AU - Capannacci, Juliana

AU - Hokama, Newton Key

AU - Nogueira, Célia Regina

AU - Ceccarelli, Michele

AU - Cerulo, Luigi

AU - D’Angelo, Fulvio

AU - de Oliveira Montandon Hokama, Paula

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib). A pool of total leukocytes from healthy donors was considered as control group. Expression analyses were performed for 768 miRNAs by RT-qPCR array. Bioinformatic tools were used to identify significant pathways and interaction networks. We found 80 deregulated miRNAs between the groups and, according to bioinformatic analysis, they are involved in different pathways, including molecular mechanisms of cancer. The study allows better understanding of disease molecular behavior, and it is useful for possible monitoring CML treatment and prognostic biomarkers identification.

AB - Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib). A pool of total leukocytes from healthy donors was considered as control group. Expression analyses were performed for 768 miRNAs by RT-qPCR array. Bioinformatic tools were used to identify significant pathways and interaction networks. We found 80 deregulated miRNAs between the groups and, according to bioinformatic analysis, they are involved in different pathways, including molecular mechanisms of cancer. The study allows better understanding of disease molecular behavior, and it is useful for possible monitoring CML treatment and prognostic biomarkers identification.

KW - Biomarkers

KW - chronic phase

KW - gene expression regulation

KW - imatinib mesylate

KW - leukemia

KW - microRNAs

KW - myeloid

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=85053345241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053345241&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1499905

DO - 10.1080/10428194.2018.1499905

M3 - Article

AN - SCOPUS:85053345241

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -